SPRTN, SprT-like N-terminal domain, 83932

N. diseases: 44; N. variants: 3
Disease: Migraine Disorders ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0149931
Disease: Migraine Disorders
Migraine Disorders 		0.040 Biomarker group BEFREE Lasmiditan demonstrated superiority to placebo in the acute treatment of migraine in adults with moderate/severe migraine disability in two similarly designed Phase 3 trials, SAMURAI and SPARTAN. 31744319 2020
CUI: C0149931
Disease: Migraine Disorders
Migraine Disorders 		0.040 Biomarker group BEFREE SAMURAI and SPARTAN were double-blind, placebo-controlled Phase 3 studies in which individuals with migraine were randomized to oral lasmiditan 50 mg (SPARTAN only), 100 mg, 200 mg, or placebo. 31409292 2019
CUI: C0149931
Disease: Migraine Disorders
Migraine Disorders 		0.040 Biomarker group BEFREE Individuals with migraine were randomized to receive oral lasmiditan 50 mg (SPARTAN only), 100 mg, 200 mg, or placebo within 4 hours of onset of a migraine attack. 31152441 2019
CUI: C0149931
Disease: Migraine Disorders
Migraine Disorders 		0.040 Biomarker group BEFREE Patients were randomized to treat a migraine attack with oral lasmiditan 50 mg (SPARTAN only), 100 mg, 200 mg, or placebo. 31340760 2019